Aligos Therapeutics, Inc. Stock-Based Compensation
Aligos Therapeutics, Inc. (ALGS) reported Stock-Based Compensation of $2.68 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-06
- Aligos Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $1.36M, a 17.59% increase year-over-year.
- Aligos Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $1.31M, a 37.02% increase year-over-year.
- Aligos Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $1.46M, a 14.49% decline year-over-year.
- Aligos Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $1.47M, a 28.19% decline year-over-year.
- Aligos Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $5.04M, a 40.32% decline from fiscal 2024.
- Aligos Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $8.45M, a 33.20% decline from fiscal 2023.
- Aligos Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $12.65M, a 13.89% decline from fiscal 2022.
- Aligos Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $14.69M, a 9.18% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $2.68M 10-Q · filed 2026-08-06 | $4.14M derived: sum of 3 quarters · filed 2026-08-06 | $5.60M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.31M 10-Q · filed 2026-05-07 | $2.77M derived: sum of 2 quarters · filed 2026-05-07 | $4.24M derived: sum of 3 quarters · filed 2026-05-07 | $5.40M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $2.92M derived: sum of 2 quarters · filed 2026-03-05 | $4.08M derived: sum of 3 quarters · filed 2026-08-06 | $5.04M 10-K · filed 2026-03-05 |
| 2025-09-30 | $1.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.63M derived: sum of 2 quarters · filed 2026-08-06 | $3.59M 10-Q · filed 2025-11-06 | $5.29M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $2.12M 10-Q · filed 2026-08-06 | $3.82M derived: sum of 3 quarters · filed 2026-08-06 | $5.87M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $959.00K 10-Q · filed 2026-05-07 | $2.66M derived: sum of 2 quarters · filed 2026-05-07 | $4.71M derived: sum of 3 quarters · filed 2026-05-07 | $6.76M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $3.75M derived: sum of 2 quarters · filed 2026-03-05 | $5.80M derived: sum of 3 quarters · filed 2026-03-05 | $8.45M 10-K · filed 2026-03-05 |
| 2024-09-30 | $2.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $4.10M derived: sum of 2 quarters · filed 2025-11-06 | $6.75M 10-Q · filed 2025-11-06 | $9.33M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $2.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $4.70M 10-Q · filed 2025-08-06 | $7.29M derived: sum of 3 quarters · filed 2025-08-06 | $10.50M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $2.65M 10-Q · filed 2025-05-06 | $5.23M derived: sum of 2 quarters · filed 2025-05-06 | $8.44M derived: sum of 3 quarters · filed 2025-05-06 | $11.64M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $2.58M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $5.79M derived: sum of 2 quarters · filed 2025-03-10 | $8.99M derived: sum of 3 quarters · filed 2025-03-10 | $12.65M 10-K · filed 2025-03-10 |
| 2023-09-30 | $3.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $6.41M derived: sum of 2 quarters · filed 2024-11-06 | $10.07M 10-Q · filed 2024-11-06 | $13.48M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $3.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $6.86M 10-Q · filed 2024-08-06 | $10.28M derived: sum of 3 quarters · filed 2024-08-06 | $13.77M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $3.66M 10-Q · filed 2024-05-07 | $7.08M derived: sum of 2 quarters · filed 2024-05-07 | $10.57M derived: sum of 3 quarters · filed 2024-05-07 | $14.57M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $3.42M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $6.91M derived: sum of 2 quarters · filed 2024-03-12 | $10.91M derived: sum of 3 quarters · filed 2024-03-12 | $14.69M 10-K · filed 2024-03-12 |
| 2022-09-30 | $3.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $7.49M derived: sum of 2 quarters · filed 2023-11-02 | $11.28M 10-Q · filed 2023-11-02 | $14.93M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $4.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $7.79M 10-Q · filed 2023-08-03 | $11.44M derived: sum of 3 quarters · filed 2023-08-03 | $15.04M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $3.79M 10-Q · filed 2023-05-04 | $7.44M derived: sum of 2 quarters · filed 2023-05-04 | $11.04M derived: sum of 3 quarters · filed 2023-05-04 | $14.49M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $3.65M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $7.25M derived: sum of 2 quarters · filed 2023-03-09 | $10.70M derived: sum of 3 quarters · filed 2023-03-09 | $13.46M 10-K · filed 2023-03-09 |
| 2021-09-30 | $3.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $7.05M derived: sum of 2 quarters · filed 2022-11-02 | $9.81M 10-Q · filed 2022-11-02 | $11.11M derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-06-30 | $3.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $6.21M 10-Q · filed 2022-08-04 | $7.51M derived: sum of 3 quarters · filed 2022-08-04 | $8.52M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $2.76M 10-Q · filed 2022-05-04 | $4.06M derived: sum of 2 quarters · filed 2022-05-04 | $5.07M derived: sum of 3 quarters · filed 2022-05-04 | $5.13M derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $2.32M derived: sum of 2 quarters · filed 2022-03-10 | $2.37M derived: sum of 3 quarters · filed 2022-03-10 | $2.98M 10-K · filed 2022-03-10 |
| 2020-09-30 | $1.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $1.07M derived: sum of 2 quarters · filed 2021-11-04 | $1.67M 10-Q · filed 2021-11-04 | $1.82M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $52.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $658.00K 10-Q · filed 2021-08-05 | $806.00K derived: sum of 3 quarters · filed 2021-08-05 | |
| 2020-03-31 | $606.00K 10-Q · filed 2021-05-10 | $754.00K derived: sum of 2 quarters · filed 2021-05-10 | ||
| 2019-12-31 | $148.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-23 | $752.00K 10-K · filed 2021-03-23 | ||
| 2019-09-30 | $604.00K 10-Q · filed 2020-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |